genae announces acquisition of e-novex

genae, a global Contract Research Organization (CRO) and services provider for the medical industries, announced today the acquisition of e-novex, a leading provider of electronic data tools that change medical research.

e-novex' proprietary Electronic Data Capture (EDC) technology is widely adopted by pharmaceutical, biotech and medical device companies, CRO's, Academic Research Organizations (ARO) and individual researchers. The portfolio comprises of e-capture.net for approval studies and the disruptive technology edc2go which allows building an electronic Case Report Form (eCRF) in a matter of hours instead of weeks or months. The core lab tracker platform facilitates the management and tracking of image logistics and enables secure transfer of large image data sets.

"The purchase of e-novex further increases genae's capacity to provide electronic solutions to our customers in the medical industries. The acquisition is also expected to result in greater eHealth efficiencies and in significantly increasing our capabilities in data management and risk based monitoring," said Bart Segers, CEO of genae.

The entire e-novex staff will be integrated in genae's e-Solutions business unit that already includes data management and statistics efficiencies. There will be no disruptions of e-novex' services during the integration which will take place over the next three months.

Source:

genae

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy